Jürgen Bader Selected Research

azido- Phe- Leu- Leu- 4- aminomethyl- Phe- methyl vinyl sulfone

8/2015

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jürgen Bader Research Topics

Disease

4	Multiple Myeloma 01/2019 - 08/2015
1	Hematologic Neoplasms (Hematological Malignancy) 03/2016
1	Neoplasms (Cancer) 08/2015
1	B-Cell Lymphoma (Lymphoma, B Cell) 08/2015
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2014

Drug/Important Bio-Agent (IBA)

5	Proteasome InhibitorsIBA 01/2019 - 03/2014
2	Nelfinavir (Viracept)FDA Link 03/2016 - 03/2014
2	Bortezomib (Velcade)FDA Link 03/2016 - 08/2015
1	SphingomyelinsIBA 01/2019
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2019
1	HIV Protease InhibitorsIBA 03/2016
1	azido- Phe- Leu- Leu- 4- aminomethyl- Phe- methyl vinyl sulfoneIBA 08/2015
1	carfilzomibIBA 08/2015
1	ibrutinibIBA 08/2015
1	Agammaglobulinaemia Tyrosine KinaseIBA 08/2015
1	I-kappa B Proteins (I kappa B)IBA 08/2015
1	Saquinavir (Invirase)FDA Link 03/2014
1	Pharmaceutical PreparationsIBA 03/2014
1	Lopinavir FDA Link 03/2014
1	Ritonavir (Norvir)FDA Link 03/2014

Therapy/Procedure

1	Therapeutics 01/2019